TLR4 signalling in the intestine in health and disease.
暂无分享,去创建一个
[1] H. Adami,et al. Ulcerative colitis and colorectal cancer. A population-based study. , 1990, The New England journal of medicine.
[2] R. Goldberg,et al. Colorectal cancer prognosis among patients with inflammatory bowel disease. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[3] M. Gazouli,et al. Association between polymorphisms in the Toll-like receptor 4, CD14, and CARD15/NOD2 and inflammatory bowel disease in the Greek population. , 2005, World journal of gastroenterology.
[4] S. Sugie,et al. Dose-dependent promoting effect of dextran sodium sulfate on mouse colon carcinogenesis initiated with azoxymethane. , 2005, Histology and histopathology.
[5] M. Abreu,et al. Decreased Expression of Toll-Like Receptor-4 and MD-2 Correlates with Intestinal Epithelial Cell Protection Against Dysregulated Proinflammatory Gene Expression in Response to Bacterial Lipopolysaccharide1 , 2001, The Journal of Immunology.
[6] F. Bäckhed,et al. Host-Bacterial Mutualism in the Human Intestine , 2005, Science.
[7] T. Ohkusa,et al. Dysplasia and carcinoma development in a repeated dextran sulfate sodium‐induced colitis model , 2002, Journal of gastroenterology and hepatology.
[8] C. Rao,et al. Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor. , 2002, Cancer research.
[9] J. Weisburger,et al. Colon carcinogenesis with azoxymethane and dimethylhydrazine in germ-free rats. , 1975, Cancer research.
[10] R. Xu,et al. Toll-like receptor-4 is required for intestinal response to epithelial injury and limiting bacterial translocation in a murine model of acute colitis. , 2005, American journal of physiology. Gastrointestinal and liver physiology.
[11] J. Weisburger,et al. Colon carcinogenesis in germ-free rats with intrarectal 1,2-dimethylhydrazine and subcutaneous azoxymethane. , 1976, Cancer research.
[12] Takuji Tanaka,et al. Strain differences in the susceptibility to azoxymethane and dextran sodium sulfate-induced colon carcinogenesis in mice. , 2006, Carcinogenesis.
[13] P. Rutgeerts,et al. Toll‐like receptor‐1, ‐2, and ‐6 polymorphisms influence disease extension in inflammatory bowel diseases , 2006, Inflammatory bowel diseases.
[14] D. Podolsky,et al. Gamma Interferon Augments the Intracellular Pathway for Lipopolysaccharide (LPS) Recognition in Human Intestinal Epithelial Cells through Coordinated Up-Regulation of LPS Uptake and Expression of the Intracellular Toll-Like Receptor 4-MD-2 Complex , 2003, Infection and Immunity.
[15] Yu-Tseung Liu,et al. Maintenance of colonic homeostasis by distinctive apical TLR9 signalling in intestinal epithelial cells , 2006, Nature Cell Biology.
[16] K. Van Steen,et al. Deficient host-bacteria interactions in inflammatory bowel disease? The toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn’s disease and ulcerative colitis , 2004, Gut.
[17] P. Jänne,et al. Chemoprevention of colorectal cancer. , 2000, The New England journal of medicine.
[18] H. Leufkens,et al. 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study , 2005, Gut.
[19] S. Akira,et al. Adjuvant-Mediated Tumor Regression and Tumor-Specific Cytotoxic Response Are Impaired in MyD88-Deficient Mice , 2004, Cancer Research.
[20] H. Cooper,et al. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. , 1993, Laboratory investigation; a journal of technical methods and pathology.
[21] T. Mussack,et al. Polymorphisms of the lipopolysaccharide-signaling complex in inflammatory bowel disease: association of a mutation in the Toll-like receptor 4 gene with ulcerative colitis. , 2004, Clinical immunology.
[22] P. Liberski,et al. Differential activation of total and EGF receptor (EGF-R) tyrosine kinase (tyr-k) in the rectal mucosa in patients with adenomatous polyps, ulcerative colitis and colon cancer. , 1997, Hepato-gastroenterology.
[23] Mitsunobu Sato,et al. Toll-like receptor signaling in anti-cancer immunity. , 2003, The journal of medical investigation : JMI.
[24] Jason M Doherty,et al. Activated macrophages are an adaptive element of the colonic epithelial progenitor niche necessary for regenerative responses to injury. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[25] D. Podolsky,et al. Mechanisms of cross hyporesponsiveness to Toll-like receptor bacterial ligands in intestinal epithelial cells. , 2004, Gastroenterology.
[26] R. Medzhitov,et al. Regulation of Spontaneous Intestinal Tumorigenesis Through the Adaptor Protein MyD88 , 2007, Science.
[27] L. Melton,et al. Risk of intestinal cancer in inflammatory bowel disease: a population-based study from olmsted county, Minnesota. , 2006, Gastroenterology.
[28] A. Kato,et al. COX‐2, prostanoids and colon cancer , 2002 .
[29] K. Michelsen,et al. Human Intestinal Epithelial Cells Are Broadly Unresponsive to Toll-Like Receptor 2-Dependent Bacterial Ligands: Implications for Host-Microbial Interactions in the Gut 1 , 2003, The Journal of Immunology.
[30] R. Xu,et al. Cox-2 is regulated by Toll-like receptor-4 (TLR4) signaling: Role in proliferation and apoptosis in the intestine. , 2006, Gastroenterology.
[31] B. Warner,et al. Epidermal growth factor is critical for intestinal adaptation following small bowel resection , 2000, Microscopy research and technique (Print).
[32] Hui Wang,et al. Experimental therapy for colon cancer: anti-cancer effects of TLR9 agonism, combination with other therapeutic modalities, and dependence upon p53. , 2007, International journal of oncology.
[33] S. Solomon,et al. Celecoxib for the prevention of sporadic colorectal adenomas. , 2006, The New England journal of medicine.
[34] S. Anant,et al. Prostaglandin E2 reduces radiation-induced epithelial apoptosis through a mechanism involving AKT activation and bax translocation. , 2004, The Journal of clinical investigation.
[35] K. Abrams,et al. Colorectal cancer prevention in ulcerative colitis: a case‐control study , 2000, Alimentary pharmacology & therapeutics.
[36] I. Azuma,et al. Role of toll-like receptors and their adaptors in adjuvant immunotherapy for cancer. , 2003, Anticancer research.
[37] R. DuBois,et al. Review article: cyclooxygenase – a target for colon cancer prevention , 2000, Alimentary pharmacology & therapeutics.
[38] Yibang Chen,et al. Toll-like receptors on tumor cells facilitate evasion of immune surveillance. , 2005, Cancer research.
[39] Alastair Forbes,et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. , 2004, Gastroenterology.
[40] G. Rogler,et al. Toll-like receptors 2 and 4 are up-regulated during intestinal inflammation. , 2001, Gastroenterology.
[41] C. A. de la Motte,et al. The Toll-interleukin-1 receptor member SIGIRR regulates colonic epithelial homeostasis, inflammation, and tumorigenesis. , 2007, Immunity.
[42] Rajnish A. Gupta,et al. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2 , 2001, Nature Reviews Cancer.
[43] R. DuBois,et al. Cyclooxygenase 2-derived prostaglandin E2 regulates the angiogenic switch. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[44] D. Palli,et al. General and cancer specific mortality of a population based cohort of patients with inflammatory bowel disease: the Florence study , 1998, Gut.
[45] Mark Tsang,et al. Dual infection with Helicobacter bilis and Helicobacter hepaticus in p-glycoprotein-deficient mdr1a-/- mice results in colitis that progresses to dysplasia. , 2005, The American journal of pathology.
[46] S. Itzkowitz. Cancer prevention in patients with inflammatory bowel disease. , 2002, Gastroenterology clinics of North America.
[47] K. Abrams,et al. The risk of colorectal cancer in ulcerative colitis: a meta-analysis , 2001, Gut.
[48] J. Gordon,et al. Commensal Host-Bacterial Relationships in the Gut , 2001, Science.
[49] Michael Karin,et al. IKKβ Links Inflammation and Tumorigenesis in a Mouse Model of Colitis-Associated Cancer , 2004, Cell.
[50] S. Itzkowitz,et al. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. , 2004, American journal of physiology. Gastrointestinal and liver physiology.
[51] R. Sartor,et al. Resident Enteric Bacteria Are Necessary for Development of Spontaneous Colitis and Immune System Activation in Interleukin-10-Deficient Mice , 1998, Infection and Immunity.
[52] A. Ekbom,et al. Is colonoscopic surveillance reducing colorectal cancer mortality in ulcerative colitis? A population based case control study , 1998, Gut.
[53] Ruslan Medzhitov,et al. Recognition of Commensal Microflora by Toll-Like Receptors Is Required for Intestinal Homeostasis , 2004, Cell.
[54] J. Wands,et al. Enhanced colon tumor induction in uncoupling protein-2 deficient mice is associated with NF-kappaB activation and oxidative stress. , 2006, Carcinogenesis.
[55] K. Uchida,et al. Intestinal microflora are necessary for development of spontaneous adenocarcinoma of the large intestine in T-cell receptor beta chain and p53 double-knockout mice. , 2001, Cancer research.
[56] S. Lippman,et al. Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[57] V. Steele,et al. Mechanisms and applications of non-steroidal anti-inflammatory drugs in the chemoprevention of cancer. , 2003, Mutation research.
[58] T. Hla,et al. Overexpression of Cyclooxygenase-2 Is Sufficient to Induce Tumorigenesis in Transgenic Mice* , 2001, The Journal of Biological Chemistry.
[59] M. Tsan. Toll-like receptors, inflammation and cancer. , 2006, Seminars in cancer biology.
[60] A. Malkinson,et al. Toll-like receptor 4 in butylated hydroxytoluene-induced mouse pulmonary inflammation and tumorigenesis. , 2005, Journal of the National Cancer Institute.
[61] J. Crusius,et al. The toll-like receptor 4 (TLR4) Asp299Gly polymorphism is associated with colonic localisation of Crohn’s disease without a major role for the Saccharomyces cerevisiae mannan-LBP-CD14-TLR4 pathway , 2005, Gut.
[62] J. Fox,et al. CD4(+)CD25(+) regulatory lymphocytes require interleukin 10 to interrupt colon carcinogenesis in mice. , 2003, Cancer research.
[63] D. Podolsky. Mechanisms of regulatory peptide action in the gastrointestinal tract: trefoil peptides. , 2000, Journal of gastroenterology.
[64] D. Podolsky,et al. Differential Alteration in Intestinal Epithelial Cell Expression of Toll-Like Receptor 3 (TLR3) and TLR4 in Inflammatory Bowel Disease , 2000, Infection and Immunity.
[65] M. Hornef,et al. Postnatal acquisition of endotoxin tolerance in intestinal epithelial cells , 2006, The Journal of experimental medicine.
[66] S. Pawlowski,et al. Elimination of colon cancer in germ-free transforming growth factor beta 1-deficient mice. , 2002, Cancer research.
[67] T. Kopp,et al. Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells , 2007, The Journal of experimental medicine.
[68] T. Ohkusa,et al. Occurrence of dysplasia and adenocarcinoma after experimental chronic ulcerative colitis in hamsters induced by dextran sulphate sodium. , 1992, Gut.
[69] David Baltimore,et al. Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-κB , 1995, Nature.
[70] H. Knutsen,et al. Identification of flat dysplastic aberrant crypt foci in the colon of azoxymethane‐treated A/J mice , 2006, International journal of cancer.
[71] T. Ohkusa,et al. Promotion of colorectal neoplasia in experimental murine ulcerative colitis. , 1996, Gut.
[72] T. Sugimura,et al. Suppression of azoxymethane-induced colonic aberrant crypt foci by a nitric oxide synthase inhibitor. , 2000, Cancer letters.
[73] Y. Whang,et al. p38 and EGF receptor kinase-mediated activation of the phosphatidylinositol 3-kinase/Akt pathway is required for Zn2+-induced cyclooxygenase-2 expression. , 2005, American journal of physiology. Lung cellular and molecular physiology.
[74] A. Forbes,et al. Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. , 2006, Gastroenterology.
[75] V. Steele,et al. Nitric oxide–releasing aspirin and indomethacin are potent inhibitors against colon cancer in azoxymethane-treated rats: effects on molecular targets , 2006, Molecular Cancer Therapeutics.
[76] G. Abrams,et al. CELLULAR RENEWAL AND MUCOSAL MORPHOLOGY IN EXPERIMENTAL ENTERITIS. INFECTION WITH SALMONELLA TYPHIMURIUM IN THE MOUSE. , 1963, Laboratory investigation; a journal of technical methods and pathology.
[77] M. Bronner,et al. The role of cyclooxygenase 2 in ulcerative colitis-associated neoplasia. , 2000, The American journal of pathology.
[78] G. T. te Meerman,et al. Association Between Toll‐like Receptor 4 and Inflammatory Bowel Disease , 2005, Inflammatory bowel diseases.
[79] C. Janeway,et al. MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways. , 1998, Molecular cell.
[80] T. Fujioka. Clarithromycin resistance in Helicobacter pylori: implications for therapy , 2000, Journal of Gastroenterology.
[81] Osamu Takeuchi,et al. Maturation of Human Dendritic Cells by Cell Wall Skeleton of Mycobacterium bovis Bacillus Calmette-Guérin: Involvement of Toll-Like Receptors , 2000, Infection and Immunity.
[82] A. Crispin,et al. The Role of Toll‐like Receptor 4 Asp299Gly and Thr399Ile Polymorphisms and CARD15/NOD2 Mutations in the Susceptibility and Phenotype of Crohn's Disease , 2005, Inflammatory bowel diseases.
[83] J. Terdiman,et al. Effect of 5-Aminosalicylate Use on Colorectal Cancer and Dysplasia Risk: A Systematic Review and Metaanalysis of Observational Studies , 2005, The American Journal of Gastroenterology.
[84] C. Pothoulakis,et al. Pathophysiological role of Toll-like receptor 5 engagement by bacterial flagellin in colonic inflammation. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[85] S. Solomon,et al. Celecoxib for the prevention of colorectal adenomatous polyps. , 2006, The New England journal of medicine.
[86] C. Jefferies,et al. Mal and MyD88: adapter proteins involved in signal transduction by Toll-like receptors , 2003, Journal of endotoxin research.
[87] J. Glas,et al. Crohn's disease is associated with a toll-like receptor-9 polymorphism. , 2004, Gastroenterology.
[88] G. Laqueur,et al. Comparison of the carcinogenicity of methylazoxymethanol-beta-D-glucosiduronic acid in conventional and germfree Sprague-Dawley rats. , 1981, Journal of the National Cancer Institute.
[89] R. DuBois,et al. Prostaglandin E2 Regulates Cell Migration via the Intracellular Activation of the Epidermal Growth Factor Receptor* , 2003, Journal of Biological Chemistry.
[90] S. Akira,et al. Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. , 2004, Gastroenterology.
[91] Jongdae Lee,et al. Immunostimulatory DNA ameliorates experimental and spontaneous murine colitis. , 2002, Gastroenterology.
[92] Benjamin P. Westover,et al. Glycan Foraging in Vivo by an Intestine-Adapted Bacterial Symbiont , 2005, Science.
[93] I. Singer,et al. Cyclooxygenase 2 is induced in colonic epithelial cells in inflammatory bowel disease. , 1998, Gastroenterology.
[94] J. Terzic,et al. Microsatelite GT polymorphism in the toll‐like receptor 2 is associated with colorectal cancer , 2006, Clinical genetics.